Volpara (ASX:VHT) share price edges lower despite biggest contract win

It seems the medical imaging company's shares are being dragged lower by broader market weakness.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Volpara Health Technologies Ltd (ASX: VHT) share price is heading south today regardless of the company's significant positive announcement.

At the time of writing, the healthcare technology company's shares are down 2.54% to $1.15.

a sonographer monitors an image of a patient's breast on a screen with the patient standing at an imaging device in the background.

Image source: Getty Images

Volpara secures largest-ever contract

According to the company's announcement, Volpara advised it has signed its biggest contract to date with a leading US outpatient diagnostic imaging provider.

The five-year deal is valued at US$2.15 million which represents an annual recurring revenue (ARR) of US$430,000.

Under the agreement, Volpara will install its Patient Hub software across the customer's network of imaging centres. The software solution is expected to provide a standardised patient tracking platform that incorporates Volpara Risk and Scorecard.

As such, this will enable the customer to accurately decide the appropriate personalised breast cancer screening pathway for each patient.

Volpara estimates that at least one of its software products is used in the breast cancer screening of more than 33% of women in the US.

Whilst the announcement is extremely positive, it appears the broader All Ordinaries Index (ASX: XAO) is weighing down the Volpara share price. The index is currently down 0.90% to 7,508.7 points.

Volpara group CEO Dr Ralph Highnam commented:

While we would not normally announce individual deals, this is Volpara's highest-value contract signed to date.

We are experiencing tremendous momentum for our platform in the market as we bring together best-of-breed patient tracking, risk assessment, and density scoring to allow our customers to provide their patients with the individualised care they deserve.

Our platform provides both Volpara and our customers with a significant advantage and is enabling us to seek out opportunities that did not exist even a couple of years ago.

About the Volpara share price

The past 12 months have been disappointing for investors with the company's shares down 13%. Year-to-date, their losses are further magnified, almost 20% lower over the period.

Based on today's price, Volpara presides a market capitalisation of roughly $29 million and has approximately 251.3 million shares outstanding.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended VOLPARA FPO NZ. The Motley Fool Australia owns shares of and has recommended VOLPARA FPO NZ. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Two CEOs shaking hands on a deal.
Healthcare Shares

Integral Diagnostics: FY26 results and new CFO appointment

Integral Diagnostics delivered double-digit profit growth and appointed a new CFO.

Read more »

Woman looking at stock market numbers.
Healthcare Shares

CSL shares are rising: 3 things investors need to watch

CSL’s FY26 result could reveal whether the turnaround has finally begun.

Read more »

Man with a sleep apnoea mask on whilst sleeping.
Healthcare Shares

Why ResMed shares are tumbling 6% today despite strong results

Here's what spooked investors.

Read more »

Scientist looking at a laptop thinking about the share price performance.
Healthcare Shares

Imricor Medical Systems shares: Philips declares compatibility for iMR products

Big news is catching the eye of investors on Friday.

Read more »

Broker looking at the share price on her laptop with green and red points in the background.
Earnings Results

ResMed posts strong Q4 earnings, lifts dividend

The sleep disorder treatment company had another record quarter.

Read more »

a doctor wearing a white coat with a stethoscope around her neck stares out a window with her hand to the side of her face as though in deep thought.
Healthcare Shares

Clarity Pharmaceuticals reports clinical trial milestones

Clarity Pharmaceuticals reported continued clinical progress for its prostate cancer imaging and therapy programs.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

Are Neuren Pharmaceuticals shares a buy, hold or sell after rocketing 16%?

This healthcare stock keeps rising.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Broker Notes

Up 64%, 3 reasons this expert predicts Pro Medicus shares will keep on giving

A leading expert forecasts more outperformance from the surging Pro Medicus share price.

Read more »